Genmab
1,462
DKK
+0.55 %
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
23 following
+0.55%
+1.11%
-14.75%
-18.64%
-32.16%
-31.39%
-40.81%
-0.31%
+4,187.39%
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
96.77B DKK
Turnover
338.56M DKK
Revenue
16.47B
EBIT %
32.3 %
P/E
21.94
Dividend yield-%
-
Financial calendar
12.2
2025
Annual report '24
12.3
2025
General meeting '24
8.5
2025
Interim report Q1'25
ShowingAll content types
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
